Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicines.
Under the agreement, Closed Loop Medicine a leading TechBio company and pharmaceutical company, Teva UK, will investigate opportunities to use Closed Loop Medicine's proprietary software as a medical device (SaMD) technology platform which aims to advance the development of personalised medicines, improve drug efficacy and outcomes in patients with specific chronic disorders by combining dose-optimised drug therapy with digital care.
Dr Paul Goldsmith, Chief Medical Officer and Innovation Officer, Co-Founder and President of Closed Loop Medicine, said: "As clinicians, we know that dosing of drugs is a huge problem. In the most extreme cases, we are seeing patients having severe adverse events, for example when required to change dose levels to undergo surgery. Being able to predict personalised dose levels could be transformational."
This strategic partnership harnesses Closed Loop Medicine's proprietary SaMD and combines it with Teva's pharmaceutical products creating the opportunity for digital companions to be prescribed alongside traditional therapeutics, enabling real-world data integration and improved effectiveness of innovative and known medicines.
Recent clinical trial results for a hypertension product, CLM-HT01, have demonstrated the technology's ability to dose optimise drug therapy and minimise side effects whilst achieving blood pressure control, with exceptionally high medication adherence.1
Personalised medicine is an aspiration of the modern healthcare system, yet existing medicines are typically prescribed based on their average effects in a population and rarely dose optimised for the individual. This "one size fits all" approach results in increased side effects and adverse reactions, medication non-adherence and consequently poorer patient outcomes and higher healthcare costs for payors. For example, the annual cost of drug-related morbidity and mortality resulting from non-optimised medication was estimated at $528.4 billion in the US, in 2016,2 and the projected annual cost of adverse drug reactions alone to the NHS is £2.21 billion.3
Kim Innes, Teva's General Manager, UK Ireland, said: "We are excited to be working with Closed Loop Medicine, who have demonstrated themselves to be compelling innovators in the area of personalised medicine. We know that the patient experience can sometimes be less than optimal and as the largest supplier of medicines to the NHS, the potential to combine 'drug' 'digital' could create significant improvements to lives of patients at great scale. We are very excited about the future of this partnership."
Dr. Hakim Yadi OBE, CEO Co-Founder of Closed Loop Medicine, commented: "It is a fantastic opportunity to be working with the Teva team to explore ways in which our combined expertise can advance the delivery of personalised medicine solutions, globally." He added: "The integration of real-world data enables personalisation of dosing that has historically not been readily available to clinicians before. This commercial partnership is an example of the potential and scalability of our SaMD technology platform, demonstrating the value that can be added by integrating software to well-known and trusted brands to improve disease management and patient outcomes at an individual level."
- Collier DJ, et al. 2024 https://www.ahajournals.org/doi/10.1161/JAHA.123.030749
- Watanabe JH, et al.2018 https://doi.org/10.1177/1060028018765159
- Osanlou R, et al. 2022 https://doi.org/10.1136/bmjopen-2021-055551
To learn more about Closed Loop Medicine, visit: www.closedloopmedicine.com
To learn more about Teva, visit www.tevapharm.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to achieve expected results from investments in our product pipeline including to successfully develop and commercialize our anti-TL1A (TEV-'574) asset for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease; our exclusive collaboration with Sanofi; the risk that we will incur significant costs in connection with the development of anti-TL1A (TEV-'574), which may exceed any revenue generated by anti-TL1A (TEV-'574); risks that regulatory approvals and other requirements may delay the development and commercialization of our anti-TL1A (TEV-'574); our ability to successfully launch and execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; our business and operations in general, including the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto; the impact of the state of war declared in Israel and the military activity in the region, including the risk of disruptions to our operations and facilities, such as our manufacturing and R&D facilities, located in Israel; and other factors discussed in this press release and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the section captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326208890/en/
Contacts:
Lily Jeffery (Zyme Communications)
Tel: +44 (0) 7891 477378
Email: lily.jeffery@zymecommunications.com
